We isolated five clinical strains (three Proteus mirabilis and two Klebsiella pneumoniae) with β-lactam resistance phenotypes consistent with production of an AmpC-type β-lactamase. The predicted amino acid sequences of the enzymes were typical of class C β-lactamases. The enzymes were identified as CMY-2, CMY-4 and a new CMY-variant β-lactamase, CMY-12. The AmpC β-lactamases from the two K. pneumoniae isolates were found to be encoded on selftransferable plasmids. The genes encoding the AmpC-type β-lactamase produced by the three P. mirabilis isolates were chromosomal. Four of the five clinical isolates were from patients transferred from Greece, Algeria and Egypt; one of the K. pneumoniae strains was recovered from a French patient. PFGE analysis and rep-PCR fingerprinting showed that the two P. mirabilis isolates from Greek patients were closely related.
Introduction
Transferable resistance to extended-spectrum cephalosporins and monobactams in Enterobacteriaceae was first described in the early 1980s. 1, 2 These enzymes evolved by multiple point mutations in the genes encoding the common plasmidmediated TEM-1, TEM-2 and SHV-1 class A enzymes. A number of other extended-spectrum β-lactamase genes, including those for BIL, CMY, LAT and MOX β-lactamases, have been reported. Nucleotide sequence analyses have shown that some of these families are closely related to the AmpC-type chromosomal β-lactamases of Citrobacter freundii (CMY-2, 3,4 CMY-3, 5 CMY-4, 6 BIL-1, 7 LAT-1, 8, 9 LAT-2 10 ), Enterobacter cloacae (MIR-1, 11, 12 ACT-1 13 ), Morganella morganii (DHA-1, 14,15 DHA-2 16 ) and Hafnia alvei (ACC-1 17, 18 ), whereas the phylogeny of others (CMY-1 types, FOX-types and MOX-1) is unclear or unknown.
Some of the newly acquired ampC genes are located on plasmids that transfer non-inducible cephalosporin resistance to Klebsiella pneumoniae, 3, 9, 12, 13, [19] [20] [21] [22] Escherichia coli, 7, 17, [22] [23] [24] Proteus mirabilis, 6, 17, 22, 23 Klebsiella oxytoca, 22, 25 Enterobacter aerogenes 10 and Salmonella sp. 4, 15, 22, 26 In addition, the first example of a chromosome-encoded AmpC β-lactamase (CMY-3) in P. mirabilis was reported recently. 5 In this study we characterized plasmid-and chromosomeencoded CMY-type β-lactamases from three clinical isolates of P. mirabilis and two clinical isolates of K. pneumoniae from Paris hospitals, and we report a new CMY β-lactamase variant.
Materials and methods

Bacterial strains
The characteristics of the clinical strains studied are summarized in Table 1 . These strains are resistant to the combination of amoxicillin with clavulanic acid (co-amoxiclav) and to cefoxitin. Two previously described CMY-type β-lactamaseproducing strains were used as controls: P. mirabilis H223b (CMY-4) 6 and Salmonella senftenberg (CMY-2). 4 The rifampicin-resistant strain of E. coli K12 J53-2 (rif R ) was used as recipient in transfer experiments.
Antibiotic susceptibility and synergy testing
MICs were determined for several β-lactams by the standard agar dilution method with Mueller-Hinton agar (Bio-Rad, Marnes la Coquette, France). Inocula (10 4 -10 5 cfu per spot) were delivered with a multipoint inoculator. Resistance to other antibiotics, such as aminoglycosides and quinolones, was determined by the disc diffusion method on MuellerHinton agar, according to the recommendations of the Comité de l'Antibiogramme de la Société Française de Microbiologie. 27 Class A extended-spectrum β-lactamases were detected by a synergy test using cefepime and co-amoxiclav. 27 Double-disc synergy tests were performed as described 15 with various cephalosporins: cefoxitin, cefotetan, ceftazidime and cefotaxime and RO48-1220 (20 µg per disc) (Hoffman-La Roche Ltd, Basel, Switzerland), which is a β-lactamase inhibitor that protects expanded-spectrum cephalosporins against strains producing group 1 and group 2be enzymes. 2 The disc with inhibitor was placed on the agar surface, 30 mm away from the central disc. 15 
β-Lactamase analysis
Analytical isoelectric focusing (IEF) was performed in ampholine polyacrylamide gels (pH 3.5-10) (PharmaciaBiotech, Saclay, France) for 18 h at 400 V, using crude cellfree sonic extracts and a Multiphor apparatus (PharmaciaBiotech). β-Lactamase activity was detected by the nitrocefin procedure. 28 The following β-lactamases (plasmid, pI) were used as standards: TEM-1 (pIP1100, pI 5.4), TEM-2 (RP4, pI 5.6), TEM-3 (pCFF04, pI 6.3), OXA-1 (RGN238, pI 7.4), SHV-4 (pUD21, pI 7.8) and CMY-2b (pSENF, pI 9.0).
PCR amplification and molecular characterization of TEM-type β-lactamases
Primers OT3 and OT4 were used to amplify putative bla TEM genes, which were characterized by PCR-RFLP analysis, as described previously. 29 PCR conditions were as follows: 3 min at 94°C, 35 cycles of 1 min at 94°C, 1 min at 55°C, 1 min at 72°C and a final extension step of 7 min at 72°C. All enzymes used were purchased from Roche Molecular Biochemicals (Meylan, France) or New England Biolabs (Ozyme, Saint Quentin en Yvelynes, France).
Sequences of class C β-lactamases
Parts of the putative class C β-lactamase genes of the three strains of P. mirabilis and the two strains of K. pneumoniae were amplified using degenerate oligonucleotide primers (ampC A1, ampC A2) based on the consensus sequence of the ampC genes of E. coli, E. cloacae and C. freundii. The sequences of primers were as follows: ampC A1 (5′-GGAAT-TCCTWTGCTGCGCBCTGCTGCT-3′) and ampC A2 (5′-CGGGATCCCTGCCAGTTTTGATAAAA-3′). 4, 6 The resulting PCR products were sequenced, as described by Sanger et al., 30 using oligonucleotide primers, fluorescently labelled dideoxynucleotides, Taq polymerase and an ABI 373A DNA sequencer (PE Applied Biosystems, Foster City, CA, USA).
The DNA sequences encoding the intact mature proteins were then amplified with the consensus primers for bla BIL-1 , bla LAT-1 , bla CMY-2 and the ampC gene of C. freundii OS60 (ampC1, 5′-ATGATGAAAAAATCGTTATGC-3′; ampC2, 5′-TTGCAGCTTTTCAAGAATGCGC-3′), and the products were sequenced as above. 4, 6 The products of two separate PCRs were sequenced on both strands.
The BLAST and FASTA programs were used to search databases for similar nucleotide and amino acid sequences. The Clustal X program was used to align multiple protein sequences. [31] [32] [33] 
Conjugation
Mating experiments were performed by mixing equal volumes (1 mL) of exponentially growing cultures of each test strain and E. coli K12 J53-2 in brain-heart infusion broth (Difco, Detroit, MI, USA) and incubating the mixture for 3 h at 37°C. β-Lactam-resistant E. coli J53-2 transconjugants were selected on Drigalski agar (Bio-Rad) containing rifampicin (256 mg/L) and cefoxitin (8 or 16 mg/L).
Plasmid analysis
Plasmid DNA was extracted from the clinical isolates of P. mirabilis and K. pneumoniae, from E. coli transconjugants and from the two control strains by alkaline lysis, as described. 34 RP4 (54 kb), pCFF04 (85 kb) and pIP173 (126.8 kb) were used as reference plasmids.
PFGE analysis
Genomic DNA, prepared as described 35 and digested with XbaI (Roche Molecular Biochemicals), was subjected to PFGE in a CHEF DRIII device (Bio-Rad). DNA fragments were separated in a 1% (w/v) agarose gel in 0.5× Tris-Borate-EDTA buffer at 200 V for 20 h, with pulse times ranging from 5 to 30 s.
Genomic fingerprinting by repetitive-element PCR (rep-PCR) analysis
rep-PCR was performed as described. 35 The primers used were REP-1R-Dt (IIINCGNCGNATCNGGC) and REP2-Dt (NCGNCTTATCNGGCCTAC). 36 The reaction was carried out in a GeneAmp PCR system 9700 (PE Applied Biosystems). Amplified DNA was analysed by agarose gel electrophoresis.
Hybridization studies
Hybridization was carried out after transfer to a nylon membrane (Hybond N, Pharmacia-Biotech) of both plasmid DNA and XbaI restriction fragments of total DNA separated by PFGE. The probe consisted of an internal DNA fragment (450 bp) from the CMY-4 ampC β-lactamase gene, obtained by PCR with degenerate primers (ampC A1 and ampC A2) and labelled with [α-32 P]dATP. 6 Nucleotide sequence accession numbers 
Results and discussion
Antibiotic susceptibility and β-lactamase analysis
All clinical isolates were highly resistant to penicillins (amoxicillin, ticarcillin, piperacillin); clavulanic acid did not significantly restore susceptibility to amoxicillin or ticarcillin ( Table 2) . As reported by others, tazobactam partially restored susceptibility to piperacillin. 4, 6, 26, 37 All of the strains were susceptible to moxalactam, cefepime and imipenem, and no synergy was observed between cefepime and co-amoxiclav. Synergy was observed between the inhibitor RO48-1220, which is active against class C β-lactamases, and the four cephalosporins tested with all of the clinical isolates (data not shown). These results suggest that each of the strains produces an AmpC-type β-lactamase. 10 IEF analysis revealed the presence of β-lactamases with pIs > 9.0 in P. mirabilis 22317, PLAR and 34955, and K. pneumoniae 169 and 9701 (data not shown). These values are consistent with production of AmpC-type β-lactamases. In addition, β-lactamases with pIs of 7.7 were detected in the two K. pneumoniae strains (169 and 9701). These enzymes are probably related to the SHV-1 chromosomal β-lactamase commonly found in this species. β-Lactamases with pIs of 5.4 were detected in P. mirabilis PLAR, P. mirabilis 22317 and K. pneumoniae 9701, and were shown to be TEM-1 by PCR-RFLP (data not shown). Finally, a β-lactamase with a pI of 5.6 detected in P. mirabilis 34955 was shown to be TEM-2 by PCR-RFLP (data not shown).
Characterization of AmpC-type β-lactamases
PCR experiments using the degenerate primers ampC A1 and ampC A2 confirmed that each of the five strains investigated produces an AmpC-type β-lactamase. The predicted amino acid sequences show that each enzyme has the β-lactamase active site SVSK, the conserved KTG triad and the typical class C YXN motif. Analysis of the partial sequences showed that all five enzymes are related to the AmpC β-lactamase of C. freundii.
Transferable class C β-lactamases have been found worldwide, most frequently in K. pneumoniae, but also in E. coli, P. mirabilis and salmonellae. CMY-2 is the most prevalent AmpC-like enzyme and has the widest geographical distribution, having been reported in Algeria, France, Germany, Greece, India, Pakistan, Taiwan, the UK and the USA, 37, 38 and recently in Spain. 22 CMY-4 was first identified in a P. mirabilis isolate from Tunisia and is also believed to originate from the chromosome of C. freundii. 6 Subsequent DNA amplifications and sequence analyses showed that the gene from K. pneumoniae 169 is 100% identical to bla CMY-2 and that the genes from P. mirabilis 22317, P. mirabilis PLAR and K. pneumoniae 9701 are 100% identical to bla . Finally, the sequence of the gene from P. mirabilis 34955 was found to be highly related to the sequences of several plasmid-mediated cephalosporinase genes related to >128  >128  >128  >128  >128  >128  >128  Co-amoxiclav a  >128  >128  >128  >128  >128  >128  >128  Ticarcillin  >128  >128  >128  >128  >128  >128  >128  Ticarcillin + clavulanic acid a  64  128  128  128  >128  >128  >128  Piperacillin  64  128  32  32  64  64  128  Piperacillin + tazobactam b  2  4  2  8  1 6  8  2  Cefalothin  >128  >128  >128  >128  >128  >128  >128  Cefamandole  >128  >128  >128  >128  >128  64  128  Cefoxitin  32  128  128  128  64  64  64  Cefotaxime  64  128  >128  8  8  32  16  Ceftazidime  32  64  >128  >128  >128  128  128  Aztreonam  1  1  2  16  4 (Table 3) . This new cephalosporinase, encoded by the gene named CMY-12, is a member of the C. freundii group and differs from other members of the group by an A171S substitution.
Transfer of resistance and plasmid analysis
E. coli J53-2 transconjugants were obtained with K. pneumoniae 169 and K. pneumoniae 9701, and the two control strains P. mirabilis H223b (CMY-4) and S. senftenberg (CMY-2) as donors. The susceptibility patterns of the transconjugants to β-lactams were found to be similar to those of the donor strains. Resistance to aminoglycosides and sulphonamides was also transferred from K. pneumoniae 9701. In contrast, attempts to transfer β-lactam resistance by conjugation from the three P. mirabilis isolates were unsuccessful. The two K. pneumoniae strains and their E. coli J53-2 transconjugants harbour large plasmids (>130 kb). A smaller plasmid (50 kb) is present in P. mirabilis 34955 (Figure 1) .
The genes for the AmpC-type β-lactamases have been located on plasmids of various sizes, from 7 to 180 kb. 37 In contrast, it was reported recently that a P. mirabilis strain harbours a chromosomal copy of an ampC homologue. 5 
Hybridization studies
To determine the location of the ampC genes in the K. pneumoniae and P. mirabilis isolates, plasmid DNA and XbaI restriction fragments of total DNA separated by PFGE were hybridized with an ampC-specific probe. The probe hybridized strongly with plasmid DNA both from K. pneumoniae 169 and 9701 and from their E. coli J53-2 transconjugants, as well as with the plasmid DNA from the control strains and their E. coli tranconjugants (Figure 1 ). In contrast, the probe did not hybridize to plasmid DNA from the three strains of P. mirabilis; the low level of hybridization observed with plasmid preparations from these strains probably corresponds to chromosomal DNA present in the extracts.
In contrast, the ampC-specific probe hybridized strongly to large XbaI restriction fragments (>400 kb), separated by PFGE, from P. mirabilis 22317, PLAR and 34955, and to a much smaller fragment from the control strain, P. mirabilis H223b, consistent with the plasmid size described previously 6 (Figure 2 ). These results suggest that the ampC genes of the three clinical isolates of P. mirabilis are chromosomal. Bret et al. 5 suggested that the ampC gene could have integrated into the chromosome of P. mirabilis via a transposon. Further studies are underway to examine this hypothesis.
Interestingly, P. mirabilis 22317 and P. mirabilis PLAR have similar PFGE profiles, suggesting a clonal origin. rep-PCR fingerprinting, which has been used for epidemiological studies of various bacterial species, 36 gave results that support this interpretation (Figure 3) , and the finding is consistent with the fact that these two P. mirabilis strains were both isolated from Greek patients from Athens.
Finally, as reported previously, 37, 39 while four of the ampC-producing strains studied here were imported, from Greece, Algeria and Egypt, K. pneumoniae 169 is the first clinical strain of this species producing a plasmid-mediated AmpC-type β-lactamase to be isolated in France from a patient who had not travelled abroad immediately prior to infection. 
